Is Eiger BioPharmaceuticals, Inc. (EIGRQ) a Buy, Sell, or Hold?
OTC : EIGRQ
Eiger BioPharmaceuticals, Inc.
$8.5 USD
$0.5 (6.25%)
- Volume
- 725
- Average Volume
- 8.26K
- Market Capitalization
- $12.59M
- P/E Ratio
- -0.17
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $16.00
- Year Low
- $1.10
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.71
Company Overview
OTC
David Apelian
Biotechnology
Healthcare
EIGRQ
25
US
USD
Liquidity Metrics
-2.85
0.71
0.68
0.48
0.00
Sales & Valuation
$15.77M
0.80
-0.87
-0.17
-50.66
Profitability
-$50.78
-$74.96M
-475.26%
-475.22%
-367.00%
-192.97%
P/E Metrics
-0.17
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-24.29
4/9
-$15.44M
$38.85M
$53.3M
-$69.49M
Key Metrics (TTM)
$28.35M
1.80
-0.41
0.71
-367.00%
-268.20%
-597.40%
-594.13%
-225 days
Company Executives
| Name | Title |
|---|---|
| James Vollins | General Counsel, Chief Compliance Officer & Corporate Secretary |
| Christopher A. Kurtz | Chief Technical Officer |
| Douglas Staut | Chief Restructuring Officer |
| David Apelian | Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Eiger BioPharmaceuticals, Inc. (OTC:EIGRQ) Stock
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical firm dedicated to discovering and advancing treatments for critical health issues, particularly hepatitis delta virus (HDV), among other severe diseases. The company's marketed product, Zokinvy, is prescribed for patients suffering from Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its development pipeline includes several key candidates: Lonafarnib: An orally administered farnesylation inhibitor that has successfully concluded Phase 3 clinical trials for HDV infection. Peginterferon Lambda (lambda): Currently in clinical development for HDV, this compound is also being investigated in Phase II and III investigator studies for mild to moderate COVID-19. Avexitide: This therapy is ... in Phase II trials for treating congenital hyperinsulinism and post-bariatric hypoglycemia. Based in Palo Alto, California, the company recently announced a significant corporate event: on April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliated entities, submitted a voluntary petition for reorganization under Chapter 11 to the U.S. Bankruptcy Court for the Northern District of Texas.
Frequently Asked Questions
-
What is the current Eiger BioPharmaceuticals, Inc. (EIGRQ) stock price?
-
Eiger BioPharmaceuticals, Inc.(OTC:EIGRQ) stock price is $8.5 in the last trading session. During the trading session, EIGRQ stock reached the peak price of $16.0 while $1.1 was the lowest point it dropped to. The percentage change in EIGRQ stock occurred in the recent session was 6.25% while the dollar amount for the price change in EIGRQ stock was $0.5.
-
EIGRQ's industry and sector of operation?
-
The OTC listed EIGRQ is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of EIGRQ?
-
James Vollins | General Counsel, Chief Compliance Officer & Corporate Secretary
Christopher A. Kurtz | Chief Technical Officer
Douglas Staut | Chief Restructuring Officer
David Apelian | Chief Executive Officer & Director
| -
How many employees does EIGRQ have?
-
Number of EIGRQ employees currently stands at 25. EIGRQ operates from 2155 Park Boulevard, Palo Alto, CA 94306, US.
-
Link for EIGRQ official website?
-
Official Website of EIGRQ is: https://www.eigerbio.com
-
How do I contact EIGRQ?
-
EIGRQ could be contacted at phone #650 272 6138 and can also be accessed through its website. EIGRQ operates from 2155 Park Boulevard, Palo Alto, CA 94306, US.
-
How many shares of EIGRQ are traded daily?
-
The average number of EIGRQ shares traded daily for last 3 months was 8.26K.
-
What is the market cap of EIGRQ currently?
-
The market value of EIGRQ currently stands at $12.59M with its latest stock price at $8.5